Cingulate (CING) Competitors

In the previous week, Surrozen had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Surrozen and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.93 beat Surrozen's score of 0.44 indicating that Cingulate is being referred to more favorably in the news media.

Cingulate has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Cingulate's return on equity.

Surrozen has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.91, suggesting that its stock price is 191% less volatile than the broader market.

Surrozen presently has a consensus price target of $42.00, indicating a potential upside of 91.96%. Cingulate has a consensus price target of $27.33, indicating a potential upside of 480.33%. Given Cingulate's higher probable upside, analysts plainly believe Cingulate is more favorable than Surrozen.

66.6% of Surrozen shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cingulate has lower revenue, but higher earnings than Surrozen. Cingulate is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Turn Therapeutics currently has a consensus target price of $8.00, indicating a potential downside of 17.01%. Cingulate has a consensus target price of $27.33, indicating a potential upside of 480.33%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than Turn Therapeutics.

Turn Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

41.3% of Cingulate shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Turn Therapeutics had 2 more articles in the media than Cingulate. MarketBeat recorded 3 mentions for Turn Therapeutics and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.93 beat Turn Therapeutics' score of 0.57 indicating that Cingulate is being referred to more favorably in the news media.

Turn Therapeutics' return on equity of 0.00% beat Cingulate's return on equity.

Siga Technologies has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.91, meaning that its stock price is 191% less volatile than the broader market.

Siga Technologies has a net margin of 21.58% compared to Cingulate's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Cingulate's return on equity.

Cingulate has a consensus price target of $27.33, suggesting a potential upside of 480.33%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Siga Technologies.

Siga Technologies has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Comparatively, 5.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Siga Technologies had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Siga Technologies and 1 mentions for Cingulate. Siga Technologies' average media sentiment score of 0.93 equaled Cingulate'saverage media sentiment score.

Cingulate has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Cingulate has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Cingulate's return on equity.

AC Immune currently has a consensus target price of $7.50, suggesting a potential upside of 211.20%. Cingulate has a consensus target price of $27.33, suggesting a potential upside of 480.33%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than AC Immune.

51.4% of AC Immune shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AC Immune has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.91, indicating that its stock price is 191% less volatile than the broader market.

In the previous week, AC Immune and AC Immune both had 1 articles in the media. AC Immune's average media sentiment score of 0.95 beat Cingulate's score of 0.93 indicating that AC Immune is being referred to more favorably in the media.